ABSTRACT
INTRODUCTION
Pre-eclampsia (PE) is a severe pregnancy-associated disease characterized by the occurrence of hypertension and proteinuria in previously healthy pregnant women after 20 weeks' gestation. PE affects approximately 2-8% of all pregnancies and is associated with substantially higher maternal and fetal morbidity and mortality worldwide 1, 2 . The clinical spectrum of PE ranges from mild PE, which is characterized by a moderate increase in blood pressure and proteinuria, to the most severe form manifesting with seizures as a sign of damage to the cerebral vessels, and HELLP syndrome, which significantly threatens the lives of pregnant women and their fetuses 3 . The true etiology of PE remains an issue of debate, which generates uncertainty in the prediction, prevention and treatment of the disease, occurring as interaction between genetic and non-genetic factors 4, 5 .
Numerous meta-analyses and systematic reviews have claimed that several environmental, biological and genetic risk factors are associated with risk for PE. If causal, these associations might be useful for the accurate prediction and diagnosis of this condition in early pregnancy, which would allow a timely allocation of screening resources and prevention of maternal and fetal complications [6] [7] [8] . In addition, preventive measures such as aspirin administration in high-risk women appear more likely to be beneficial if started earlier in pregnancy, i.e. during the first trimester or even before conception 9, 10 . Nevertheless, it is possible that some associations observed in the literature do not reflect a genuine result but include different types of bias in favor of positive statistically significant associations 11 . The pursuit of positive results may be generated by several different mechanisms 12 , such as selective analyses, outcome bias and fabrication bias 13 . These biases can cause either false published findings or inflated effects 12, 14 .
To our knowledge, this is the first attempt to summarize evidence from existing meta-analyses on genetic and non-genetic risk factors for PE. We aimed to summarize evidence on risk factors that have been associated with PE, evaluate whether biases are present in the literature and how they manifest and finally identify which of the previously studied associations are supported by robust epidemiological evidence.
METHODS

Umbrella review
This was an umbrella review, which is a systematic collection and evaluation of multiple systematic reviews and meta-analyses performed on a specific research topic 15 . An umbrella review brings together comparisons of a large number of existing systematic reviews and meta-analyses into one accessible and practical document 15, 16 . The methods of the umbrella review are standardized and in this work we followed state-of-the-art approaches, as seen in other previously published umbrella reviews on risk factors and various outcomes [17] [18] [19] [20] .
Literature search
Two researchers (K.G. and S.P.) independently searched PubMed and ISI Web of Science from inception to 8 October 2016, to identify systematic reviews and meta-analyses of observational studies examining associations between risk factors and PE. The search strategy used the keywords ('pre-eclampsia' OR 'preeclampsia') AND ('systematic review' OR 'meta-analysis'). First, the title and abstract of each article identified through the search were examined, and then the full texts of potentially eligible articles were retrieved for evaluation. PubMed was also searched systematically to identify genome-wide association studies examining genetic associations with PE. Any discrepancies were resolved by discussion.
Eligibility criteria and data extraction
Articles were eligible for inclusion if the authors had performed a systematic search to identify pertinent studies that examined the association between various risk factors and PE. The full texts of potentially eligible articles were scrutinized independently by two investigators (K.G., S.P.). Meta-analyses or systematic reviews were retained if they included at least three studies in which information per included study was provided on a measure of association and its standard error (SE) between the risk factor and PE and on the number of cases per population in each study included in the meta-analysis. We excluded studies in which risk factors were used for screening, diagnostic or prognostic purposes, or meta-analyses that examined PE as a risk factor for other medical conditions. No language restriction was applied. If more than one meta-analysis on the same research question was eligible, the one with the largest number of component studies with data on effect size of individual studies was retained for the main analysis. Data extraction was performed independently by two investigators (K.G., S.P.), and in case of disagreement, the final decision was reached by discussion between them or, if necessary, by review by a third investigator (E.E.). From each eligible meta-analysis, information was extracted on the first author, year of publication, examined risk factors, number of studies included, study-specific relative risk estimates (risk ratio, odds ratio) or standardized mean differences along with the corresponding CIs. Also, reported summary meta-analytic estimates were recorded using both fixed-and random-effects methods along with the corresponding CIs and the number of cases and controls for each study. We noted whether or not the selected meta-analyses applied any criteria to evaluate the quality of the included observational studies.
Assessment of summary effect and heterogeneity
For each meta-analysis, the summary effects with 95% CIs were estimated using both fixed-and random-effects models 21, 22 . Additionally, the 95% prediction intervals (PI) were calculated for the summary random-effects estimates, which further account for between-study heterogeneity and indicate the uncertainty for the effect that would be expected in the new study observing the same association 23, 24 . The SE of the effect size was calculated for the largest study of each meta-analysis, and we examined whether it was < 0.10 and whether the largest study presented a statistically significant effect. In a study with a SE of < 0.10, the difference between the effect estimate and the upper or lower 95% CI is < 0.20 (i.e. this uncertainty is less than what is considered a small effect size).
Heterogeneity between studies was assessed, and we reported the P-value of the χ 2 -based Cochran Q test and the I 2 statistic for inconsistency, which could reflect either diversity or bias. I 2 ranges between 0% and 100% and indicates the ratio of between-study variance over the sum of within and between-study variances 25 . Values exceeding 50% or 75% are usually considered to represent large or very large heterogeneity, respectively. CIs were calculated as per Ioannidis et al. 26 .
Assessment of small-study effect
The presence of the small-study effect (i.e. if small studies tend to give higher risk estimates than large studies) was evaluated. The small-study effect can indicate publication and other selective reporting biases, but can also reflect genuine heterogeneity, chance or other reasons for differences between small and large studies 27 . The regression asymmetry test proposed by Egger et al. 28 was used for this assessment. P < 0.10 accompanied by a more conservative effect in larger studies was considered evidence for the presence of a small-study effect.
Evaluation of excess statistical significance
The excess-of-statistical-significance test was performed to evaluate whether there was a relative excess of formally significant findings in the published literature for any reason. The number of expected positive studies is estimated and compared with the observed number of studies with statistically significant results (P < 0.05) 13 . A binomial test was used to evaluate whether the number of positive studies in a meta-analysis was too large according to the power that these studies have to detect plausible effects at α = 0.05. A comparison between observed and expected studies with statistically significant results is performed separately for each meta-analysis, and it is extended to groups of several meta-analyses after summing the observed and expected studies from each meta-analysis. The power of each component study was estimated using the fixed-effects summary, the random-effects summary, or the effect size of the largest study (smallest SE) as the plausible effect size 29 . The power of each study was calculated with an algorithm using a non-central t distribution 30 . Excess statistical significance for single meta-analyses was claimed at P < 0.10 (one-sided P < 0.05, with observed > expected as previously proposed), given that the power to detect a specific excess will be low, especially with few positive studies 13 . Risk factors were classified, based on biological pathways or types of exposure involved, into the following categories: biomarkers, environmental factors, genetic markers, diseases and disorders, dietary supplementation, infections and other risk factors. Excess statistical significance was examined separately in each of these categories, as selective reporting bias may arise in different domains of research. The excess-of-statistical-significance test was conducted separately for meta-analyses with I 2 values ≤ 50% and those with values > 50%, because values above 50% typically reflect evidence of large heterogeneity beyond chance 31 .
Grading of non-genetic and genetic associations with PE
The association of non-genetic risk factors with PE was characterized as: (a) 'convincing' if the effect under the random-effects model was significant at P < 10 -6 , it was based on evidence arising from > 1000 cases, between-study heterogeneity was not large (I 2 < 50%), the 95% PI excluded the null value and there was no evidence of small-study effects and excess of significance bias; (b) 'highly suggestive' if the effect was significant at P < 10 -6 , it was based on > 1000 cases and a nominally statistically significant effect was present in the largest study; (c) 'suggestive' if the effect was significant at P < 10 -3 and it was based on >1000 cases; and (d) 'weak' for statistically significant associations at P < 0.05 based on the random-effects model.
The Venice criteria were used to evaluate the epidemiological credibility of all significant genetic associations 32 . Credibility was defined based upon the grade (A = strong, B = moderate or C = weak) of three categories: amount of evidence, replication of the association and protection from bias. The amount of evidence was graded by the sum of test alleles or genotypes among both cases and controls in the meta-analysis: 'A' for > 1000, 'B' for 100-1000, and 'C' for < 100. Replication of the association was graded as 'A' if there was an extensively replicated study supported by at least one well-conducted meta-analysis, 'B' if it was a well-conducted meta-analysis with some methodological limitations and 'C', if there was no independent replication, failed replication or flawed meta-analysis. Assessment of protection from bias included consideration of the magnitude of the association, heterogeneity statistic and findings from tests for selective reporting biases (tests for small-study effects and excess statistical significance). According to these criteria, the credibility level of the cumulative evidence was defined as high (A grades only), low (one or more C grades) or intermediate (all other combinations) 32 . All authors had full access to all data in the study. Statistical analysis and power calculations were performed in STATA version 14 (STATA Corp., College Station, TX, USA).
RESULTS
Description of eligible meta-analyses
The search identified 635 items, of which 535 were excluded after review of the title and abstract ( Figure 1) . Of the remaining 100 articles that were reviewed in full text, eight articles did not report the appropriate PE as a risk factor for other outcomes (n = 77) Study of efficacy of treatments (n = 48) Diagnostic, prognostic or screening study (n = 22) Intervention study for prevention of PE (n = 119) Outcome other than PE (n = 76) Incidence or prevalence study (n = 8) Editorial or narrative review (n = 39) Methodological study (n = 14)
References excluded (n = 132): Primary studies (n = 6) PE as a risk factor for other outcomes (n = 22) Study of efficacy of treatments (n = 10) Diagnostic, prognostic or screening study (n = 4) Intervention study for prevention of PE (n = 30) Editorial or narrative review (n = 29) Outcome other than PE (n = 28) Incidence or prevalence study (n = 3)
References excluded (n = 29): Pooled analysis of cohort studies (n = 1) Meta-analysis with only two component studies (n = 2) Duplicate data/largest systematic review or meta-analysis investigating same risk factor (n = 18) Appropriate information not available for required calculations (n = 8) Systematic reviews included in qualitative synthesis (n = 13)
References identified (n = 635)
Titles reviewed (n = 635)
Abstracts reviewed (n = 232) Articles reviewed (n = 100)
Articles included (n = 71) Figure 1 Flowchart showing systematic reviews and meta-analyses of observational studies reporting on genetic and non-genetic factors associated with pre-eclampsia (PE), included in this umbrella review.
information for the calculation of excess of statistical significance (either because the total sample size was missing or the study-specific relative risk estimates were missing), one article was a pooled analysis of cohort studies, two articles included only two component studies, and 18 articles were excluded because a larger systematic review or meta-analysis investigating the same risk factor was available. Therefore, 71 articles were analyzed, of which 13 were systematic reviews without any quantitative component and 58 were meta-analyses. The 58 eligible meta-analyses 5,33-89 included data on 130 comparisons in seven broad areas (biomarkers (27 comparisons), environmental factors (six comparisons), genetic markers (66 comparisons), diseases and disorders (eight comparisons), supplementation (one comparison), infections (three comparisons) and other risk factors (19 comparisons) ).
The characteristics of the included meta-analyses are shown in Table S1 . Based on the study design of the synthesized studies that examined non-genetic associations, seven (20%) meta-analyses synthesized retrospective case-control data only, three (9%) included prospective data (cohort studies) and 25 (71%) included both types of data, noted as mixed. With respect to the genetic association studies, 15 (65%) meta-analyses synthesized case-control data, seven (30%) used both types of data (case-control and cohort data), and one (4%) meta-analysis included only cohorts.
Three to 51 studies, with a median of eight studies, were included per meta-analysis. The median number of case and control subjects in each study was 96 and 161, respectively. The median number of case and control subjects in each meta-analysis was 1123 and 3598, respectively. The number of cases was greater than 1000 in 70 comparisons. Overall, 441 (30%) individual studies observed nominally statistically significant results. Twenty-one (36%) meta-analyses used the Newcastle-Ottawa Scale to assess qualitatively the included primary studies. Two meta-analyses used assessment criteria for non-randomized observational studies adapted from Duckitt and Harrington, two meta-analyses used the Methodological Index for Non-Randomized Studies (MINORS) and nine meta-analyses used other assessment tools. Twenty-four (41%) meta-analyses did not perform any quality assessment. Details of the 130 comparisons that included 1466 individual study estimates are summarized in Table S2 .
Systematic reviews with qualitative synthesis
We also summarized evidence of systematic reviews that did not include any quantitative component [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] . According to the findings of these studies, serum calprotectin and cardiac troponin-I levels were elevated in women with PE compared with healthy controls, and cell-free fetal DNA quantification has been shown to be a promising marker for PE prediction, especially for the development of early-onset or severe PE [90] [91] [92] . PE was more prevalent in cold and humid seasons 93 , and a long interpregnancy interval, possibly longer than 5 years, was also associated independently with an increased risk for PE 94 . Psychotropic drugs such as lithium for the management of antenatal psychiatric disorders have also been associated with PE 95 . Pregnant women with systemic lupus erythematosus or Cushing's syndrome are at higher risk of developing PE compared with healthy pregnant women 96, 97 . Laparoscopic adjustable gastric band (LAGB) surgery seems to improve pregnancy outcome for conditions such as PE in obese women, compared with those who do not have LAGB 98, 99 . Limited evidence was found on whether shift work, HIV infection or antiretroviral therapy, and thrombophilic disorders are associated with an increased risk for PE [100] [101] [102] .
Summary-effect sizes and significant findings
Of the 130 comparisons, 65 (50%) had nominally statistically significant findings at P < 0.05 using the random-effects model, of which 53 reported an increased risk and 12 a decreased risk for PE. Of these, a total of 28 (22%) associations presented statistically significant effect at P < 0.001, while only 16 (12%) remained significant after the application of a more stringent P-value threshold of P < 10 -6 (Table S1 ). The sixteen risk factors that presented a significant effect at P < 10 -6 for an association with PE were: serum iron level, pregnancy-associated plasma protein-A (PAPP-A), placental protein 13, placental growth factor (PlGF), F5 rs6025, F2 rs1799963, chronic kidney disease, polycystic ovary syndrome (PCOS), mental stress, bacterial and viral infections, cigarette smoking, oocyte donation vs assisted reproductive technology (ART), oocyte donation vs normal conception, obesity vs normal weight, severe obesity vs normal weight and primiparity.
Across the seven categories of risk factors, differences were observed in the proportion of associations that had nominally statistically significant summary effects. Based on random effects calculations at P < 0.05, 100%, 75%, 63% and 59% of the meta-analyses on infections, diseases and disorders, other risk factors and biomarkers, respectively, found nominally statistically significant summary effects. On the other hand, this was seen only in 39% and 33% of the meta-analyses on genetic markers and environmental factors, respectively.
Between-study heterogeneity and prediction intervals
Thirty-three (25%) comparisons had large (I 2 ≥ 50% and ≤ 75%) and 32 (25%) had very large (I 2 > 75%) heterogeneity estimates (Table S1 ). The highest proportion (56%) of I 2 exceeding 75% was observed in comparisons of biomarkers. When calculating the 95% PIs, the null value was excluded in only 14 (11%) comparisons. This included two comparisons on biomarkers (PAPP-A and Vitamin D < 50 mmol/L), five on genetic markers (G20210A single nucleotide polymorphism (SNP), PAI-1 4G/5G, F5 rs6025, F2 rs1799963, AGT/T704C-Met235Thr), two on diseases and disorders (chronic kidney disease and PCOS) and five on other risk factors (oocyte donation vs ART, oocyte donation vs spontaneous conception, high vs low levels of physical activity in early pregnancy, obese vs normal weight and primiparity) (Table S1 ).
Small-study effects
Evidence for statistically significant small-study effects (Egger test P < 0.10 and random-effects summary estimate larger compared with the point estimate of the largest study in the meta-analysis) was identified in 10 of 130 (8%) comparisons (Table S2) . These included two meta-analyses on biomarkers (PAPP-A, PlGF), one on environmental factors (oxides of nitrogen), four on genetic markers (NOS3 27 bp-VNTR in intron 4, F2 rs1799963, ACE rs4646994, ACE-I/D), two on diseases and disorders (PCOS and mental stress) and one on other risk factors (prepregnancy physical activity of 1 h per day).
Test of excess statistical significance
Hints of excess-statistical-significance bias were observed in 26 (20%) associations, with statistically significant (P < 0.05) excess of positive studies under any of the three assumptions for the plausible effect size, i.e. the fixed-effects summary, random-effects summary or results of the largest study (Table S2 ). Of these, 10 (38%) pertained to biomarkers, nine (35%) to genetic markers, three (12%) to diseases and disorders and four (15%) to other risk factors. In addition, the observed and expected number of positive studies showed that, overall, the excess of positive results was driven by meta-analyses with small estimates of heterogeneity (I 2 ≤ 50%). The results of excess-of-statistical-significance bias according to category of risk factor are shown in Table 1 .
Risk factors with strong evidence of association
After applying our credibility criteria, only one nongenetic risk factor, oocyte donation vs spontaneous conception, presented convincing evidence for an association with PE, i.e. it was supported by data from more than 1000 cases, P < 10 -6 based on the random-effects model, there was an absence of small-study effects and excess statistical significance, low heterogeneity (I 2 < 50%) and a 95% PI excluding the null value. This association had a summary odds ratio (OR) of 4.33 (95% CI, 3.11-6.03; P = 3.48 × 10 -18 ) with small heterogeneity (I 2 = 26%), and was supported by 2712 cases.
Moreover, 11 risk factors (serum iron level, PAPP-A, chronic kidney disease, PCOS, mental stress, bacterial and viral infections, cigarette smoking, oocyte donation vs ART, obesity vs normal weight, severe obesity vs normal weight and primiparity) presented highly suggestive evidence for an association with PE, five risk factors were supported by suggestive evidence, and 22 by weak evidence. An overall assessment of statistically significant associations of risk factors with PE is presented in Table 2 . Table 1 Excess of statistical significance bias according to category of risk factor associated with pre-eclampsia, based on expected number of studies with statistically significant findings estimated using fixed-effects summary, random-effects summary, effect of largest study and most conservative of three estimates (composite) Data are n. *P of excess of statistically significant test; all statistical tests were two-sided. Expected number of statistically significant studies using as plausible effect size: †summary fixed-effects estimate of each meta-analysis; ‡summary random-effects estimate of each meta-analysis; §effect of largest study of each meta-analysis; ¶most conservative of three estimates (fixed-effects summary, random-effects summary, largest study) of each meta-analysis. NP, not pertinent, because estimated is larger than observed, and there is no evidence of excess of statistical significance based on assumption made for plausible effect size. per day §, early pregnancy walking §, donor insemination * P-value on meta-analysis random-effects model. †Small-study effect based on P-value from Egger's regression asymmetry test (P < 0.10). ‡P < 0.05 on excess significance test using largest study (smallest standard error) in a meta-analysis as plausible effect size. §Factors that show a protective effect against developing pre-eclampsia. ART, assisted reproductive technology; β-hCG, β-human chorionic gonadotropin; IFN-γ, interferon gamma; NO, nitric oxide; NO 2 , nitrogen dioxide; O 3 , ozone; PA, physical activity; PAPP-A, pregnancy-associated plasma protein-A; PlGF, placental growth factor; PP-13, placental protein 13; sENG, soluble endoglin; sFlt-1, soluble fms-like tyrosine kinase-1; 25 (OH) D, 25-hydroxyvitamin D.
Cumulative epidemiological evidence for genetic associations with PE was scored as strong, moderate or weak based on grades of 'A', 'B' or 'C', as specified by the Venice criteria. Of the 26 variants with significant associations with risk of PE, according to P < 0.05 using the random-effects model, only the PAI-1 4G/5G polymorphism (recessive model) was supported by strong evidence for a contribution to the pathogenesis of PE (Table 3) .
Independent tool-based quality assessment of primary studies
The quality of the included studies of the meta-analysis of the non-genetic risk factor that presented convincing evidence for an association with PE was also assessed using the Newcastle-Ottawa Scale in addition to the MINORS scale that the authors used in the original assessment 103 . The methodological quality ranged from 3 points to 8 points maximally, with a median of 6 points, which implies a fair quality for the majority of studies. Quality assessment was also performed among the included studies of meta-analysis of the PAI-1 4G/5G polymorphism using the Q-Genie tool 104 . Among the reviewed studies, eight (67%) were rated to have high quality (> 45) and four (33%) were rated to have moderate quality (> 35 and ≤ 45).
DISCUSSION
Main findings
Overall, 130 associations have been studied as risk factors for PE, including biomarkers, genetic markers, environmental factors, supplementation, diseases and disorders, infections and other risk factors. Of those, oocyte donation vs spontaneous conception provided convincing evidence for an association with PE. PAI-1 4G/5G (recessive model) polymorphism was supported by strong evidence for a contribution to the pathogenesis of PE, as specified by the Venice criteria. Eleven risk factors from various categories achieved highly suggestive evidence for an association with PE.
Interpretation
PE remains a 'disease of theories', as a large number of factors and a genetic component are probably involved in its pathogenesis, but to date none has been established clearly. From a biological standpoint, oocyte donation can act as an independent risk factor for the development of PE. During normal pregnancy, various immunosuppressive mechanisms maintain a diminished innate immune response in order to prevent fetal rejection, as the fetal tissue is exposed directly to the maternal blood and, hence, is at risk of being attacked by components of both the innate and the acquired immune systems 105, 106 . A fetus conceived spontaneously is a semi-allograft, in which both maternal and paternal genes are expressed, whereas a fetus conceived through oocyte donation is an absolute allograft, and this could lead to altered or inadequate immune protection of placentation and eventually result in PE [107] [108] [109] [110] . This theory is further supported by the observation that oocyte donation vs other assisted reproduction techniques had highly suggestive evidence of epidemiological credibility. Moreover, immune dysregulation may explain the highly suggestive evidence of an increased risk of PE among primiparous women because the first successful (non-pre-eclamptic) pregnancy may induce adaptive changes in favor of immune tolerance in subsequent pregnancies 89 . The genetic architecture behind PE is complex 111 . To date, most research in this field has been focused on candidate genes, primarily those with a plausible role in the known underlying pathophysiology 112 . We identified only three genome-wide association studies, which included several genetic loci associated with PE [113] [114] [115] . One study identified two loci (rs7579169 and rs12711941) near the inhibin beta B gene that satisfied the genome-wide significance threshold 114 , but the results could not be replicated in two cohorts from Norway and Finland. Subsequent case-control studies in European and Chinese women have shown a significant association between the SNP rs7579169 and PE 116, 117 . Eleven factors (serum iron level, PAPP-A, chronic kidney disease, PCOS, mental stress, bacterial and viral infections, cigarette smoking, oocyte donation vs ART, obesity/severe obesity vs normal weight, primiparity) achieved highly suggestive evidence for an association with PE. There are several mechanisms that support these findings. With respect to biomarkers, iron is considered a significant etiologic factor of the endothelial cell damage in PE because of its effects on the formation of oxygen free radicals and subsequent lipid peroxidation [118] [119] [120] . Reduced levels of PAPP-A, being an important regulator of insulin-like growth factor, can play a role in the development of PE in pregnancies with normal karyotype 121 .
Renal insufficiency, maternal hypertension, proteinuria and recurrent urinary tract infection, which often coexist in women with chronic kidney disease, may contribute individually and cumulatively to PE [122] [123] [124] . Insulin resistance and/or associated hyperglycemia, which is/are often present in PCOS and obese patients, could be a possible explanation of a higher risk for PE, since they might directly predispose women to hypertension through increased renal sodium re-absorption and stimulation of the sympathetic nervous system and/or may impair endothelial function 125 . Increased levels of androgens in PCOS pregnancies have also been associated with the development of PE 126 . Cigarette smoking during pregnancy seems to have a protective effect against the development of PE. Experimental studies have demonstrated that carbon monoxide decreases the levels of antiangiogenic factors such as soluble fms-like tyrosine kinase-1 and soluble endoglin, or increases the levels of angiogenic factors like vascular endothelial growth factor 127 , which are thought Only first author of each study is given. *Summary random effects odds ratio (95% CI) of each meta-analysis. †P-value from Egger regression asymmetry test for evaluation of publication bias. ‡I 2 metric of inconsistency and P-value of Cochran Q test for evaluation of heterogeneity. §Based on P-value (P < 0.05) of excess significance test using largest study (smallest standard error) in a meta-analysis as plausible effect size. ¶Venice criteria grades are in order of amount of evidence, replication of association and protection from bias. **Cumulative epidemiological evidence as graded by Venice criteria as strong (+++), moderate (++) or weak (+) for association with pre-eclampsia risk. ACE, angiotensin; AGT, angiotensinogen; AT2R, angiotensin type 2 receptor; FVL, factor V Leiden; IL-10, interleukin-10; LEPR, leptin receptor; LPL, lipoprotein lipase; MMP-9, matrix metallopeptidase-9; MTHFR, methylene tetrahydrofolate reductase; PAI-1, plasminogen activator inhibitor-1; SNP, single-nucleotide polymorphism; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor. to be involved in the pathogenesis of PE [128] [129] [130] . Infection may play an important role in the pathogenesis of PE, either through initiation of the condition by increasing the risk of acute uteroplacental atherosclerosis and/or its enhancement by magnifying the maternal systemic inflammatory response 131 , or through a direct effect on trophoblast cells by destruction or impairment, resulting in shallow invasion of maternal spiral arteries 132 .
Strengths and limitations
Both Egger and excess-of-significance tests offer hints of bias, not definitive proof thereof, while the Egger test is difficult to interpret when between-study heterogeneity is large. The frequency of meta-analyses with small-study asymmetry effects was not high (8%), and this rate is commensurate with chance. Nevertheless, our estimates are likely to be conservative, as a negative test result does not exclude the potential for bias. The majority of the included studies for non-genetic associations were retrospective, which is indicative of a higher inherent potential for bias. However, by performing a standardized methodological process for the assessment of the epidemiological credibility of the findings using a variety of tests, we succeeded in combining all these biases, and provide a complete picture of the totality of the evidence as it stands today. The findings of the excess-of-statistical-significance test for the results of a single meta-analysis, especially one with few studies, should be interpreted with caution because a negative test does not exclude the potential for bias 13 . Furthermore, quality assessment of the primary studies was highly heterogeneous, reflecting the lack of standardized quality assessment methodologies.
Conclusion
Oocyte donation vs spontaneous conception was supported by convincing evidence, and 11 risk factors achieved highly suggestive evidence for an association with PE. PAI-1 4G/5G (recessive model) polymorphism was supported by strong evidence for a contribution to the pathogenesis of PE. The use of standardized definitions and protocols for exposures, outcomes and statistical analyses 133, 134 , adoption of reporting guidelines (e.g. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and STrengthening the REporting of Genetic Association Studies (STREGA)) and registration of hypothesis-testing observational studies [135] [136] [137] [138] , may help to improve the evidence in the future, diminish the risk of biases and improve the reliability of this important literature.
Factores de riesgo genéticos y no genéticos para la preeclampsia: resumen de revisiones sistemáticas y metaanálisis de estudios observacionales RESUMEN Objetivo Resumir la evidencia de la literatura sobre factores de riesgo genéticos y no genéticos asociados con la preeclampsia (PE), evaluar la existencia de sesgos estadísticos en los estudios e identificar los factores de riesgo para los cuales existe evidencia sólida que respalde su asociación con la PE.
Métodos Se realizaron búsquedas en PubMed e ISI Web of Science desde su inicio hasta octubre de 2016, a fin de identificar revisiones sistemáticas y metaanálisis de estudios observacionales que examinaron las asociaciones entre factores de riesgo genéticos o no genéticos y la PE. Para cada metaanálisis, el tamaño del efecto resumen se estimó mediante modelos de efectos aleatorios y de efectos fijos, con un IC del 95% y un intervalo de predicción del 95%. La heterogeneidad entre estudios se expresó utilizando el estadístico I 2 y la evidencia de efectos de estudios pequeños (los estudios grandes tuvieron resultados significativamente más conservadores que los estudios más pequeños) y se estimó la evidencia de sesgo por exceso de significación (demasiados estudios con resultados estadísticamente significativos).
Resultados Se identificaron cincuenta y ocho posibles metaanálisis, que incluían 1466 estudios primarios y proporcionaban datos sobre 130 comparaciones de factores de riesgo asociados con la PE, que cubren una amplia gama de enfermedades concomitantes, factores genéticos, exposición a agentes ambientales y biomarcadores. Sesenta y cinco (50%) asociaciones mostraron nominalmente hallazgos estadísticamente significativos con una P<0,05, mientras que 16 de ellas (12%) fueron significativas con una P<10-6. Sesenta y cinco (50%) asociaciones mostraron una heterogeneidad grande o muy grande. Se encontró evidencia de efectos de estudios pequeños y sesgos por exceso de significación en 10 (8%) y 26 (20%) asociaciones, respectivamente. Elúnico factor de riesgo no genético con evidencia convincente de una asociación con la PE fue la donación de ovocitos en comparación con la concepción espontánea, que tuvo una razón de momios resumen de 4,33 (IC 95%, 3,11-6,03), fue respaldada por 2712 casos con una heterogeneidad pequeña (I 2 = 26%) e intervalos de predicción del 95% excluyendo el valor nulo, y sin indicios de efectos de estudios pequeños (P para la prueba de Egger > 0,10) o sin un exceso de significación (P > 0,05). Entre los factores de riesgo genéticos estadísticamente significativos (P<0.05) para la PE, tan solo el polimorfismo PAI-1 4G/5G (modelo recesivo) fue respaldado por una evidencia fuerte de contribución a la patogenia de la PE. Once factores presentaron evidencia que sugería en gran medida una asociación con la PE (nivel de hierro sérico, proteína plasmática A asociada al embarazo, enfermedad renal crónica, síndrome de ovario poliquístico, estrés mental, infecciones bacterianas y virales, tabaquismo, donación de ovocitos frente a la tecnología de reproducción asistida, obesidad frente a peso normal, obesidad severa frente a peso normal y primiparidad).
